FDA
-
-
-
-
-
-
-
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
-
-
-
-
-
-
-
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
-
-
-
-
-
-
-
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
-
-
-
-
-
-
-
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
-
-
-
-
-
-
-
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
-
-
-
-
-
-
-
How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection
-
-
-
-
-
-
-
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
-
326,258 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

